Loading...
XTSX
VPT
Market cap12mUSD
, Last price  
CAD
Name

VentriPoint Diagnostics Ltd

Chart & performance

D1W1MN
XTSX:VPT chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
17.29%
Rev. 5Y
37.95%
Div Yld LY
—
Div Yld TTM
—
Revenues
180k
+89.06%
00000151,720372,28971,019128,31355,783209,47938,90560,17781,02336,017068,16749,18395,172179,928
Net income
-3m
L-34.95%
0000000000-2,623,752-3,703,202-2,084,014-3,322,628-1,850,676-3,881,030-4,872,800-4,871,937-4,919,573-3,200,243
CFO
-2m
L-54.08%
0000000000-2,199,422-3,069,984-3,048,987-2,381,290-1,100,354-3,146,764-4,136,742-3,803,894-3,386,199-1,554,919

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

VentriPoint Diagnostics Ltd. is a medical technology company focused on developing and commercializing diagnostic tools worldwide. These innovative solutions are designed to monitor individuals afflicted with cardiovascular disease. At the core of their offerings is the Ventripoint Medical System (VMS), an advanced medical imaging platform. The VMS generates precise three-dimensional models of the heart's chambers, providing crucial volumetric and functional measurements. This system is further enhanced by its VMS+ software, which processes echocardiogram and magnetic resonance imaging (MRI) data to construct these 3D models. The VMS+ software ensures highly reproducible and accurate quantification of heart chamber volumes and ejection fraction. Beyond its current flagship system, VentriPoint Diagnostics is actively expanding its portfolio with a suite of specialized applications. These applications target various cardiac conditions and imaging techniques, including congenital heart disease, pulmonary hypertension, cardiotoxicity in oncology patients, and heart complications stemming from Covid-19. Founded in 2004, the company operates from its headquarters in Toronto, Canada.

Key people

Executive Chairman of the Board · since 2023
Alvira Macanovic
President, Chief Executive Officer · since 2023
David Swetlow
Chief Financial Officer · since 2025
Thomas Brown
Director - Congenital Heart Defect Program · since 2025
Randy AuCoin
Independent Director · since 2021
Fiona Fitzgerald
Independent Director · since 2021
Independent Director · since 2019
Hugh MacNaught
Independent Director · since 2020
IPO date
Nov 09, 2005
Employees
Domiciled in
CA
Incorporated in
CA
Headquarters & legal address
18 Hook Avenue, Unit 101
Toronto, ON M6P 1T4
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT